Home | Careers | Contact Us Diagnostics Diagnostics Overview BioReference Laboratories 4Kscore Test Point-of-Care Diagnostics Platform Therapeutics Therapeutics Overview Renal Biologics OPKO-CURNA Protein-Based Vaccines Asthma & COPD Parkinson’s Disease CINV Products Overview OPKO Chile OPKO EU OPKO FineTech OPKO Mexico OPKO Mexico Privacy Policy / Aviso de Privacidad EirGen Pharma Patents Strategic Investments Strategic Investments Overview Investor Relations Press Releases Conferences & Events Corporate Governance SEC Filings Stock Performance Investor Faq Email Alerts 2016 Annual Report 2017 Proxy Statement Forms 8937 OPKO Health Inc. PROLOR Biotech Inc. BioReference Laboratories Inc. Transition Therapeutics About Us Company Overview Management Team Board of Directors Scientific Advisory Board Careers Contact Us Biomarker Discovery Team OPKO Careers OPKO Chile OPKO-CURNA OPKO Diagnostics OPKO EU OPKO FineTech OPKO Mexico Transformative Diagnostics Next-Generation Therapies & Vaccines Addressing large, unmet global markets with innovative proprietary products More » Worldwide Production & Distribution Capitalizing on high-value, emerging markets for pharmaceutical and diagnostic products More » Strategic Investments Identifying early-stage companies with potential to increase value for shareholders More » Chairman’s Message OPKO continues to make progress with its program to build a company capable of long-term growth and increasing value to its investors and I would like to review several highlights. OPKO Completes Acquisition of Bio-Reference Laboratories. OPKO Letter to Shareholders» News & Events more news » Sep. 19, 2017 OPKO's BioReference Laboratories and The Garage Announce National Strategic Affiliation to Enhance Value-Based Care more » Sep. 12, 2017 OPKO's GeneDx to Showcase Leadership in Genetic Testing at the National Society of Genetic Counselors and the American Society of Human Genetics Annual Meetings more » Aug. 31, 2017 OPKO Health to Present at Upcoming September Conferences more » Investors read more » OPKO Health is an opportunistic research and development company that targets large, high-growth markets. FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease click here » © 2014 OPKO Health Inc.- All rights reserved. Contact Us Privacy Policy Terms Of Use